menu
    • menu
    [{"orgOrder":0,"company":"Abata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ABA-201","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Abata Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Abata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ABA-101","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Abata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Abata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ABA-101","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Abata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Abata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abata Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"ABA-101","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Abata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abata Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Abata Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Abata Therapeutics","sponsor":"Third Rock Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Abata Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abata Therapeutics \/ Third Rock Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Abata Therapeutics \/ Third Rock Ventures"}]

    Find Clinical Drug Pipeline Developments & Deals by Abata Therapeutics

    Menu

    Abata Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Abata Therapeutics

                            U.S.A arrow
                            CST
                            Not Confirmed

                            Abata Therapeutics

                            U.S.A arrow
                            CST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABA-101

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Abata Therapeutics Gets FDA Clearance for ABA-101 in Progressive Multiple Sclerosis

                            Details : ABA-101 is an autologous Treg therapy for progressive multiple sclerosis. It engineers a patient’s Tregs to express a TCR that targets immunogenic myelin fragments in the CNS.

                            Product Name : ABA-101

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            September 07, 2024

                            Lead Product(s) : ABA-101

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Abata Therapeutics

                            U.S.A arrow
                            CST
                            Not Confirmed

                            Abata Therapeutics

                            U.S.A arrow
                            CST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABA-101

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Abata Therapeutics Gets FDA Fast Track for ABA-101 in Progressive MS

                            Details : ABA-101 is an autologous Treg therapy csndidate, which is currently under development for the treatment of patients with progressive multiple sclerosis.

                            Product Name : ABA-101

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            August 22, 2024

                            Lead Product(s) : ABA-101

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Abata Therapeutics

                            U.S.A arrow
                            CST
                            Not Confirmed

                            Abata Therapeutics

                            U.S.A arrow
                            CST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABA-101

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Abata Receives Bristol Myers Investment For Treg Therapy Development

                            Details : The proceeds will support the development of Abata's Treg cell therapy products, including ABA-101 being developed for the treatment of progressive multiple sclerosis.

                            Product Name : ABA-101

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            August 15, 2024

                            Lead Product(s) : ABA-101

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Abata Therapeutics

                            U.S.A arrow
                            Breast Cancer
                            Not Confirmed

                            Abata Therapeutics

                            U.S.A arrow
                            Breast Cancer
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABA-201

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Abata Therapeutics Announces Second Development Candidate, ABA-201, a Novel Treg Cell Therapy for the Treatmen...

                            Details : ABA-201 is Abata’s autologous Treg therapy in development for the treatment of T1D. It targets T1D patients who have remaining beta cell function and a specific HLA genetic haplotype.

                            Product Name : ABA-201

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            August 24, 2023

                            Lead Product(s) : ABA-201

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Abata Therapeutics

                            U.S.A arrow
                            CST
                            Not Confirmed

                            Abata Therapeutics

                            U.S.A arrow
                            CST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Third Rock Ventures

                            Deal Size : $95.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Abata Therapeutics Launches to Usher in New Era of Cell Therapy Using Targeted Regulatory T Cells

                            Details : Abata’s autologous Treg cell therapies are engineered to express T cell receptors (TCRs) that recognize antigens present in tissue where an autoimmune response has been triggered.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            June 23, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Third Rock Ventures

                            Deal Size : $95.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth